• MSCs demonstrate significant potential for treating diabetes mellitus, with high safety and efficacy.
• Autologous MSCs offer better clinical outcomes than allogenic sources, and BMMSCs are more effective than other MSC types.
• MSCs show superior therapeutic benefits compared to monocytes, with notable improvements in glycemic control and complications.
• The meta-analysis highlights the importance of MSC source and delivery route in optimizing diabetes treatment outcomes.